Novo Nordisk
NVO
#14
Rank
โ‚ฌ539.10 B
Marketcap
121,63ย โ‚ฌ
Share price
2.06%
Change (1 day)
39.25%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

Novo Nordisk (NVO) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : โ‚ฌ33.36 B

According to Novo Nordisk's latest financial reports the company's total liabilities are โ‚ฌ33.36 B. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Novo Nordisk - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31โ‚ฌ27.85 B31.52%
2022-12-31โ‚ฌ21.18 B27.89%
2021-12-31โ‚ฌ16.56 B50.1%
2020-12-31โ‚ฌ11.03 B21.48%
2019-12-31โ‚ฌ9.08 B15.24%
2018-12-31โ‚ฌ7.88 B11.65%
2017-12-31โ‚ฌ7.05 B0.33%
2016-12-31โ‚ฌ7.03 B16.92%
2015-12-31โ‚ฌ6.01 B21.98%
2014-12-31โ‚ฌ4.93 B32.57%
2013-12-31โ‚ฌ3.72 B10.79%
2012-12-31โ‚ฌ3.35 B-8.11%
2011-12-31โ‚ฌ3.65 B11.21%
2010-12-31โ‚ฌ3.28 B28.52%
2009-12-31โ‚ฌ2.55 B8.76%
2008-12-31โ‚ฌ2.35 B13.77%
2007-12-31โ‚ฌ2.06 B5.6%
2006-12-31โ‚ฌ1.95 B2.39%
2005-12-31โ‚ฌ1.91 B44.24%
2004-12-31โ‚ฌ1.32 B6.47%
2003-12-31โ‚ฌ1.24 B2.41%
2002-12-31โ‚ฌ1.21 B-17.35%
2001-12-31โ‚ฌ1.47 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
โ‚ฌ115.70 B 246.77%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ52.55 B 57.51%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ70.00 B 109.81%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ54.90 B 64.55%๐Ÿ‡ซ๐Ÿ‡ท France